Latest Clinical trial Stories
- Patients in the 30 mcg sufentanil NanoTab treatment group experienced significantly greater reduction in pain as measured by SPID-12 vs. placebo - REDWOOD CITY, Calif., April 24, 2013 /PRNewswire/ --- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line results demonstrating that a placebo-controlled,...
ORLANDO, Fla., April 23, 2013 /PRNewswire/ -- Intelsius, a DGP company, a designer, manufacturer and distributor of temperature-controlled packaging solutions, introduces the first of its kind range of solutions, BioCarrier(TM), specifically designed for local courier routes and multiple site sample collections. (Photo: http://photos.prnewswire.com/prnh/20130423/DE98247 )(Logo: http://photos.prnewswire.com/prnh/20120215/DE53620LOGO ) "Intelsius is proudly introducing the...
Lazarex will be recognized on the evening of Wednesday, June 5, 2013 at the? Westin Boston Waterfront DANVILLE, Calif., April 23, 2013 /PRNewswire/ -- Lazarex Cancer Foundation has been selected as part of this year's "The One Hundred" by Massachusetts General Hospital Cancer Center. Mass General Cancer Center picks 100 individuals and groups whose diligence and discoveries, philanthropy and passion have helped advance the fight against cancer. Past honorees have included doctors,...
HEAT Study Analysis Shows ThermoDox® Improves Progression Free Survival (PFS) and Overall Survival (OS) when Heating is Optimized LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. Celsion is evaluating ThermoDox® in a Phase III clinical...
NEW YORK, April 23, 2013 /PRNewswire/ -- Intralinks® Holdings, Inc. (NYSE: IL), a leading, global SaaS provider of inter-enterprise content management and collaboration solutions, today announced the results of the 2013 Intralinks Global Investigator Site Survey. The survey looked at how clinical investigator sites currently perceive clinical web portals. The findings revealed that 80% of respondents agreed that a single web portal with one login to access studies across multiple...
CLEVELAND, April 23, 2013 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced an Israeli biopharmaceutical company chose to standardize on the DATATRAK ONE(TM) clinical research platform for its oncology program. Understanding the benefit of the unified platform, they will utilize multiple products and modules within the...
By the National Cancer Institute Editor's Note: The following article is part of the monthly Lifelines education and awareness print series that the National Cancer Institute provides to African American news and information outlets BETHESDA, Md., April 22, 2013 /PRNewswire-USNewswire/ -- In communities of color, the words "clinical trial" or "research study" sometimes raise concerns that are rooted in memories of infamous studies of the past, such as the Tuskegee Syphilis Study....
2013 Bio-IT World Best of Show Winner in Clinical Trials Category CONSHOHOCKEN, Pa., April 22, 2013 /PRNewswire/ -- ePharmaSolutions, a leading clinical services and eClinical solutions provider, won the Best of Show category for Clinical Trials at the 2013 Bio-IT World Conference and Expo held in Boston last week. Selected as a finalist by a panel of expert, industry judges, two teams of onsite judges viewed the finalist products and demonstrations on Wednesday at the event....
New Non-Surgical Medical Device Achieves Surgical-Level Weight-Loss Results and Has the Potential to be Safer and More Cost-Effective than Bariatric Surgery GOLETA, Calif., April 22, 2013 /PRNewswire/ -- BAROnova, Inc., recently presented data from their ENDObesity I clinical trial at the annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting. During the study, which was conducted in Sydney, Australia, obese subjects with a BMI ranging from 30-50 kg/m(2)...
SANTIAGO, Chile, April 18, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Company will be conducting a meeting with clinical investigators in Santiago, Chile, on April 18th, 2013. The meeting will include presentations about the upcoming Phase II clinical study investigating the use of TI-001, intranasal oxytocin, for the treatment of...
